Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.15 USD
Change Today +0.01 / 0.32%
Volume 2.2M
EXEL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

exelixis inc (EXEL) Snapshot

Open
$3.14
Previous Close
$3.14
Day High
$3.16
Day Low
$3.04
52 Week High
07/28/14 - $4.55
52 Week Low
12/23/14 - $1.26
Market Cap
617.5M
Average Volume 10 Days
4.1M
EPS TTM
$-1.15
Shares Outstanding
196.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXELIXIS INC (EXEL)

exelixis inc (EXEL) Related Businessweek News

No Related Businessweek News Found

exelixis inc (EXEL) Details

Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising approximately 45 clinical trials, including 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC). In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase 3 pivotal trial evaluating in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

85 Employees
Last Reported Date: 04/30/15
Founded in 1994

exelixis inc (EXEL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $755.2K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $318.9K
Executive Vice President and Chief Medical Of...
Total Annual Compensation: $513.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $407.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $380.8K
Compensation as of Fiscal Year 2014.

exelixis inc (EXEL) Key Developments

Exelixis, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 12:00 PM

Exelixis, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 12:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Michael M. Morrissey, Chief Executive Officer, President and Director.

Exelixis, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Exelixis, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company’s net product revenues were $9,388,000 against $4,905,000 a year ago. Loss from operations was $22,760,000 against $64,988,000 a year ago. Net loss was $35,170,000 against $74,619,000 a year ago. Net loss per share, basic and diluted was $0.18 against $0.39 a year ago. Net revenues consisted entirely of product revenue related to the sale of COMETRIQ. The decreased net loss for the quarter was primarily due to decreases in research and development expenses and selling, general and administrative expenses and an increase in product revenues.

Exelixis, Inc. to Report Q1, 2015 Results on Apr 30, 2015

Exelixis, Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on Apr 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXEL:US $3.15 USD +0.01

EXEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.71 USD -0.03
Curis Inc $3.04 USD -0.06
Cytokinetics Inc $6.22 USD -0.05
Evotec AG €4.02 EUR +0.018
Rigel Pharmaceuticals Inc $3.56 USD -0.12
View Industry Companies
 

Industry Analysis

EXEL

Industry Average

Valuation EXEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXELIXIS INC, please visit www.exelixis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.